Kentucky reaches OxyContin, Risperdal settlements; Valeant's Walgreens pact won't solve its growth problems;

> Kentucky has reached two separate settlements totaling $39.5 million--one each with Purdue and Johnson & Johnson ($JNJ) over their respective meds, OxyContin and Risperdal. More

> Valeant's ($VRX) new pricing and distribution pact with Walgreens ($WBA) likely won't bring the company the same revenue growth it generated with high-priced branded drugs, doctors and investors say. More

> India has added drugs for cancer, HIV/AIDS and hepatitis C to its essential medicines list in hopes of making them more affordable. More

> The New England Journal of Medicine has published positive results of two trials of Novartis' ($NVS) Cosentyx in ankylosing spondylitis. Release

And Finally... The U.S. Drug Enforcement Agency (DEA) is easing the regulatory requirements that were previously imposed on those conducting FDA-approved clinical trials on cannabidiol. More

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.